loading
Schlusskurs vom Vortag:
$4.15
Offen:
$4.18
24-Stunden-Volumen:
185.00K
Relative Volume:
0.91
Marktkapitalisierung:
$98.40M
Einnahmen:
$7.95M
Nettoeinkommen (Verlust:
$-21.23M
KGV:
-3.4944
EPS:
-1.2005
Netto-Cashflow:
$-11.90M
1W Leistung:
-5.73%
1M Leistung:
-16.93%
6M Leistung:
-21.00%
1J Leistung:
-35.95%
1-Tages-Spanne:
Value
$4.15
$4.39
1-Wochen-Bereich:
Value
$4.02
$4.4825
52-Wochen-Spanne:
Value
$3.9401
$7.75

Coya Therapeutics Inc Stock (COYA) Company Profile

Name
Firmenname
Coya Therapeutics Inc
Name
Telefon
650.739.3939
Name
Adresse
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
2026-03-17
Name
Neueste SEC-Einreichungen
Name
COYA's Discussions on Twitter

Compare COYA vs VRTX, REGN, ALNY, ARGX, INSM

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
COYA icon
COYA
Coya Therapeutics Inc
4.195 97.35M 7.95M -21.23M -11.90M -1.2005
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
454.97 115.58B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
749.47 79.23B 14.34B 4.50B 3.77B 41.56
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
328.70 43.59B 3.71B 313.75M 465.38M 2.2571
ARGX icon
ARGX
Argen X Se Adr
697.05 43.26B 4.16B 1.29B 734.26M 19.58
INSM icon
INSM
Insmed Inc
148.31 31.97B 606.42M -1.28B -997.58M -6.403

Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-09 Eingeleitet Lake Street Buy
2024-12-04 Eingeleitet D. Boral Capital Buy

Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten

pulisher
Mar 25, 2026

HC Wainwright Analysts Decrease Earnings Estimates for COYA - MarketBeat

Mar 25, 2026
pulisher
Mar 24, 2026

Sell Signal: How much upside does Coya Therapeutics Inc have2026 Big Picture & Expert Approved Momentum Trade Ideas - baoquankhu1.vn

Mar 24, 2026
pulisher
Mar 24, 2026

ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President a - PharmiWeb.com

Mar 24, 2026
pulisher
Mar 24, 2026

What is HC Wainwright's Estimate for COYA Q1 Earnings? - MarketBeat

Mar 24, 2026
pulisher
Mar 24, 2026

Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Mar 24, 2026
pulisher
Mar 23, 2026

Coya Therapeutics' (COYA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Mar 23, 2026
pulisher
Mar 23, 2026

Coya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy Rating - TipRanks

Mar 23, 2026
pulisher
Mar 23, 2026

Coya Therapeutics (COYA) Analyst Rating Reiterated at 'Buy' by H - GuruFocus

Mar 23, 2026
pulisher
Mar 23, 2026

[EFFECT] Coya Therapeutics, In... | COYA SEC FilingForm EFFECT - Stock Titan

Mar 23, 2026
pulisher
Mar 21, 2026

ALDX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 21, 2026
pulisher
Mar 21, 2026

Coya Therapeutics (NASDAQ:COYA) Downgraded to Sell Rating by Wall Street Zen - MarketBeat

Mar 21, 2026
pulisher
Mar 20, 2026

CEO Moves: Can Coya Therapeutics Inc sustain earnings growthInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn

Mar 20, 2026
pulisher
Mar 20, 2026

2.52M-share resale registration by Coya Therapeutics (NASDAQ: COYA) after Jan 2026 placement - Stock Titan

Mar 20, 2026
pulisher
Mar 19, 2026

Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail

Mar 19, 2026
pulisher
Mar 18, 2026

FinancialContentCoya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy - FinancialContent

Mar 18, 2026
pulisher
Mar 17, 2026

COYA SEC FilingsCoya Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 17, 2026
pulisher
Mar 17, 2026

Coya Therapeutics (COYA) Deepening Losses Challenge Bullish Growth Narrative After FY 2025 Results - simplywall.st

Mar 17, 2026
pulisher
Mar 17, 2026

Aggressive Treg-Modulating Immunology Strategy and Advancing Clinical Execution Underpin Buy Rating on Coya in ALS and FTD - TipRanks

Mar 17, 2026
pulisher
Mar 17, 2026

CGTX PE Ratio & Valuation, Is CGTX Overvalued - Intellectia AI

Mar 17, 2026
pulisher
Mar 17, 2026

Treasury Yields: Is Coya Therapeutics Inc impacted by rising ratesBull Run & High Yield Equity Trading Tips - baoquankhu1.vn

Mar 17, 2026
pulisher
Mar 17, 2026

Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World

Mar 17, 2026
pulisher
Mar 16, 2026

Coya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 16, 2026
pulisher
Mar 16, 2026

COYA: Chardan Capital Maintains 'Buy' Rating with $14 Price Targ - GuruFocus

Mar 16, 2026
pulisher
Mar 16, 2026

D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

Coya Therapeutics Reports 2025 Financial Results and Advances ALS & FTD Clinical Trials with Strong Cash Position - Minichart

Mar 16, 2026
pulisher
Mar 16, 2026

Coya Therapeutics: Advancing Treg-Based Therapies for Neurodegenerative and Autoimmune Diseases - Minichart

Mar 16, 2026
pulisher
Mar 16, 2026

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results - BioSpace

Mar 16, 2026
pulisher
Mar 16, 2026

Coya Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

Coya Therapeutics Incfiles for resale of up to 2.5 million shares of common stock by selling stockholdersSEC filing - marketscreener.com

Mar 16, 2026
pulisher
Mar 16, 2026

Coya Therapeutics (NASDAQ: COYA) registers 2.52M private‑placement shares for resale - Stock Titan

Mar 16, 2026
pulisher
Mar 16, 2026

Coya Therapeutics provides a corporate update and reports fiscal 2025 financial results - marketscreener.com

Mar 16, 2026
pulisher
Mar 16, 2026

Coya Therapeutics (NASDAQ:COYA) Announces Quarterly Earnings Results - MarketBeat

Mar 16, 2026
pulisher
Mar 16, 2026

Coya Therapeutics 2025 10-K: $7.95M Revenue; $(21.23)M Net Loss - TradingView

Mar 16, 2026
pulisher
Mar 16, 2026

ALS Treg pipeline and runway into 2027 at Coya Therapeutics (NASDAQ: COYA) - Stock Titan

Mar 16, 2026
pulisher
Mar 16, 2026

Coya Therapeutics (NASDAQ: COYA) reports 2025 results, funds runway into 2H 2027 - Stock Titan

Mar 16, 2026
pulisher
Mar 15, 2026

Coya Therapeutics receives $4.2M milestone payment - MSN

Mar 15, 2026
pulisher
Mar 13, 2026

Form 13G Coya Therapeutics For: 12 March By Investing.com - Investing.com Australia

Mar 13, 2026
pulisher
Mar 12, 2026

Dr. Reddy's takes 9.7% stake in Coya Therapeutics (COYA) via subsidiary - Stock Titan

Mar 12, 2026
pulisher
Mar 10, 2026

BTIG Maintains Coya Therapeutics (COYA) Buy Recommendation - MSN

Mar 10, 2026
pulisher
Mar 10, 2026

Coya Therapeutics (COYA) to Release Quarterly Earnings on Tuesday - MarketBeat

Mar 10, 2026
pulisher
Mar 07, 2026

Is Coya Therapeutics Inc. impacted by rising ratesMarket Trend Report & Intraday High Probability Alerts - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 07, 2026

Aug Reactions: Is Coya Therapeutics Inc impacted by rising ratesLayoff News & Technical Buy Zone Confirmations - baoquankhu1.vn

Mar 07, 2026
pulisher
Mar 06, 2026

Stock Analysis: Is Coya Therapeutics Inc impacted by rising rates2025 Market WrapUp & AI Enhanced Trading Signals - baoquankhu1.vn

Mar 06, 2026
pulisher
Mar 04, 2026

Aug Mood: Is Coya Therapeutics Inc benefiting from innovation trendsEarnings Overview Report & AI Driven Stock Reports - baoquankhu1.vn

Mar 04, 2026
pulisher
Mar 04, 2026

COYA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 04, 2026
pulisher
Feb 28, 2026

New Highs: Is Coya Therapeutics Inc impacted by rising rates - baoquankhu1.vn

Feb 28, 2026
pulisher
Feb 28, 2026

Trading the Move, Not the Narrative: (COYA) Edition - Stock Traders Daily

Feb 28, 2026
pulisher
Feb 27, 2026

Coya Therapeutics, Inc. (NASDAQ:COYA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Feb 27, 2026
pulisher
Feb 26, 2026

Should I buy Coya Therapeutics Inc. stock nowGDP Growth & Real-Time Sentiment Analysis - mfd.ru

Feb 26, 2026
pulisher
Feb 26, 2026

Coya Therapeutics, Inc. (COYA) upgraded to buy: What does it mean for the stock? - MSN

Feb 26, 2026

Finanzdaten der Coya Therapeutics Inc-Aktie (COYA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$27.36
price up icon 1.82%
$47.03
price up icon 3.20%
$53.54
price up icon 4.29%
$88.77
price up icon 2.26%
ONC ONC
$283.45
price up icon 2.81%
$148.31
price up icon 6.59%
Kapitalisierung:     |  Volumen (24h):